See more : Angus Gold Inc. (ANGVF) Income Statement Analysis – Financial Results
Complete financial analysis of MDB Capital Holdings, LLC Class A common (MDBH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MDB Capital Holdings, LLC Class A common, a leading company in the Financial – Capital Markets industry within the Financial Services sector.
You may be interested
- AJ Bell plc (AJB.L) Income Statement Analysis – Financial Results
- Forterra plc (FORT.L) Income Statement Analysis – Financial Results
- Concord Acquisition Corp III (CNDB) Income Statement Analysis – Financial Results
- Great Elm Capital Corp. 5.875% Notes due 2026 (GECCO) Income Statement Analysis – Financial Results
- Danaos Corporation (DAC) Income Statement Analysis – Financial Results
MDB Capital Holdings, LLC Class A common (MDBH)
About MDB Capital Holdings, LLC Class A common
MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business. The company was founded in 1997 and is based in Addison, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 4.23M | 1.12M | 3.19M | 12.11M |
| Cost of Revenue | 8.63M | 2.82M | 1.97M | 1.78M |
| Gross Profit | -4.39M | -1.71M | 1.22M | 10.32M |
| Gross Profit Ratio | -103.80% | -153.16% | 38.33% | 85.27% |
| Research & Development | 528.18K | 348.09K | 454.45K | 577.17K |
| General & Administrative | 4.22M | 2.68M | 1.92M | 1.07M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.22M | 2.68M | 1.92M | 1.07M |
| Other Expenses | -638.51K | 227.25K | 251.86K | 4.00 |
| Operating Expenses | 4.11M | 4.41M | 3.76M | 2.47M |
| Cost & Expenses | 12.74M | 7.23M | 5.72M | 4.25M |
| Interest Income | 919.35K | 227.25K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 196.94K | 7.31M | 19.11M | 13.34M |
| EBITDA | -8.26M | -5.97M | -15.88M | -1.19M |
| EBITDA Ratio | -195.04% | -536.81% | 134.20% | -59.72% |
| Operating Income | -8.50M | -6.10M | -15.92M | -1.23M |
| Operating Income Ratio | -200.87% | -547.29% | -499.71% | -10.18% |
| Total Other Income/Expenses | 919.35K | 227.25K | 251.86K | 0.00 |
| Income Before Tax | -7.58M | -5.88M | -15.67M | -1.23M |
| Income Before Tax Ratio | -179.15% | -526.91% | -491.80% | -10.18% |
| Income Tax Expense | 127.92K | -803.69K | 9.38M | 40.07K |
| Net Income | -6.97M | -5.31M | -15.10M | -722.18K |
| Net Income Ratio | -164.63% | -476.60% | -473.83% | -5.97% |
| EPS | -0.86 | -0.63 | -1.78 | -0.09 |
| EPS Diluted | -0.86 | -0.63 | -1.78 | -0.09 |
| Weighted Avg Shares Out | 8.10M | 8.46M | 8.46M | 8.46M |
| Weighted Avg Shares Out (Dil) | 8.10M | 8.46M | 8.46M | 8.46M |
MDB Capital Holdings Provides Third Quarter 2024 Update
Addison, TX, Nov. 21, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to the quarter ended September...
Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development
MDB Capital Holdings to Host Third Quarter 2024 Results Conference Call on Thursday November 21, 2024, at 4:30 p.m. Eastern Time
Addison, Texas, Nov. 15, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Thursday November 21, 2024 at 4:30 p.m. Eastern...
Invizyne Technologies Announces Closing of Initial Public Offering
Monrovia, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the closing of its initial public offering of...
Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing
Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of...
Invizyne Technologies Begins Trading on NASDAQ
Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024
Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering
Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC” Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC”
MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies
Record date of July 22, 2024 set for allocation preferences Closing and trading expected on NASDAQ on or before August 15 Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform...
Recently Published Whitepaper from PatentVest Delves into Transformative Innovations in MASH Diagnostics
Transformative Innovations in MASH Diagnostics Dallas, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- PatentVest, the first integrated IP intelligence strategy and law firm, recently published a whitepaper that presents strategic insights in the fields of Metabolic-Associated Steatohepatitis (MASH) biomarkers and...
Source: https://incomestatements.info
Category: Stock Reports